低分子量肝素治疗不稳定型心绞痛临床观察

Clinical observation of low molecular weight heparin in treating patients with unstable angina pectoris

目的 观察低分子量肝素 (L MWH)治疗不稳定性心绞痛 (UAP)的疗效及不良反应。方法 选择UAP住院患者 80例 ,随机分为 L MWH治疗组及对照组各 4 0例。治疗组患者皮下注射 L MWH Fraxiparine(速避凝 ) 4 10 0 Axa IU,每日 2次 ,共 10 d;其他治疗包括抗血小板和抗心绞痛等常规治疗。对照组除不用 L MWH外 ,其他治疗与治疗组相同。结果 治疗 15 d后 ,治疗组与对照组治疗总有效率分别为 90 .0 %与 6 7.5 % ;不良心脏事件 (急性心肌梗死与猝死 )发生率分别为 2 .5 %与 2 0 .0 % ;差异有显著性 (P<0 .0 5 )。未见出血等严重不良反应。结论 L MWH治疗 U AP疗效显著 。

Objective To observe the clinical effect and side effects of low molecular weight heparin (LMWH) on unstable angina pectoris(UAP).Methods The clinical study was conducted in eighty administered patients with UAP.They were randomly divided into two groups.The control group( n =40,aspirin 80 mg once daily po) and LMWH treat group( n =40,aspirin 80 mg once daily po and LMWH Fraxiparine 4100 Axa IU subcutaneously injeced twice daily for 10 days).Basic routine antianginal treatment(β blockers?calcium antagonsists?nitrates)were given at the same time.The changes of angina symptom,consumed doses of nitrates,rest electrocardiogram(ECG),heart rate(HR),blood pressure(BP),myocardial oxygen consumption and routine laboratory tests were observed before and 15 days after the treatment.Results After treatment for 15 days,the total effective rates were 90.0% in the group treated with LMWH and 67.5% in control group respectively.The rate of bad cardiac events(death and AMI)was low in group treated with LMWH than those in control group(2.5% vs 20.0%, P < 0.05 ).No obivous side effects(such as bleeding)were observed in both groups.Conclusion LMWH is effective and safe in treating patients with UAP.